N-乙氧羰基-7-氧代十字孢碱 | 143086-33-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: N-乙氧羰基-7-氧代十字孢碱
• 中文别名: 单-异戊基2,3-二巯基琥珀酸酯
• 英文名称: N-Ethoxycarbonyl-7-oxostaurosporine
• 英文别名: ethyl N-[(2S,3S,4R,6S)-3-methoxy-2-methyl-16,18-dioxo-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-4-yl]-N-methylcarbamate
• CAS: 143086-33-3
• 化学式: C₃₁H₂₈N₄O₆
• 分子量: 552.6
• InChiKey: YYDZNUMDZXMMCI-ZEMYHKRKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  41
• 可旋转键数：
  4
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  104
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
  申请人：Griffin Douglas James

  公开号：US20050020570A1

  公开（公告）日：2005-01-27

  The present invention relates to the use of staurosporines derivatives for the preparation of a drug for the treatment of diseases involving deregulated FLT3 receptor tyrosine kinase activity, especially for the curative and/or prophylactic treatment of leukemias and myelodysplastic syndromes, and to a method of treating diseases involving deregulated FLT3 receptor tyrosine kinase activity.

  本发明涉及使用司陶孢烯类衍生物制备药物，用于治疗涉及FLT3受体酪氨酸激酶活性失调的疾病，特别是用于治疗和/或预防性治疗白血病和骨髓增生异常综合征，还涉及一种治疗涉及FLT3受体酪氨酸激酶活性失调的疾病的方法。
• Organic compound
  申请人：Si Ming-Sing

  公开号：US20050159404A1

  公开（公告）日：2005-07-21

  A combination which comprises (a) a staurosporine derivative and (b) an agent effective in preventing, delaying or treating transplant rejection in which the active ingredients (a) and (b) are present in each case in free form or in the form of a pharmaceutically acceptable salt and optionally at least one pharmaceutically acceptable carrier; for simultaneous, separate or sequential use.

  一种复方制剂，包括(a)司陶罗孢林衍生物和(b)一种有效预防、延缓或治疗移植排斥反应的制剂，其中活性成分(a)和(b)在每种情况下均以游离形式或以药学上可接受的盐的形式存在，并可选择至少一种药学上可接受的载体；可同时、单独或连续使用。
• Staurosporine derivatives for hypereosinophilic syndrome
  申请人：Gilliland Gary D.

  公开号：US20060229290A1

  公开（公告）日：2006-10-12

  The present invention relates to the use of staurosporine derivatives for the preparation of a drug for the treatment of FIP1L1-PDGFRα-induced myeloproliferative diseases, especially for the curative and/or prophylactic treatment of hypereosinophilic syndrome and hypereosinophilic syndrome with resistance to imatinib, and to a method of treating hypereosinophilic syndrome and hypereosinophilic syndrome with resistance to imatinib, or other diseases associated with FIPL1-PDGFRa or similar mutations that activate PDGFRα.

  本发明涉及司陶孢林衍生物用于制备治疗FIP1L1-PDGFRα诱导的骨髓增生性疾病的药物的用途，特别是用于治疗和/或预防性治疗高嗜酸性粒细胞综合征和对伊马替尼耐药的高嗜酸性粒细胞综合征、以及治疗对伊马替尼耐药的高嗜酸性粒细胞增多综合征和高嗜酸性粒细胞增多综合征，或其他与 FIPL1-PDGFRa 或激活 PDGFRα 的类似突变有关的疾病的方法。
• STAUROSPORINE DERIVATIVES AS INHIBITORS OF FLT3 RECEPTOR TYROSINE KINASE ACTIVITY
  申请人：Novartis AG

  公开号：EP1441737B1

  公开（公告）日：2006-08-09
• COMBINATIONS COMPRISING STAUROSPRORINES
  申请人：Novartis AG

  公开号：EP2037933A2

  公开（公告）日：2009-03-25